Background Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase and
tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration …

Background Although androgen receptor-targeted agents prolong the lives of patients with
metastatic prostate cancer, patients develop therapy resistance and most ultimately …

Purpose: In patients with metastatic castration-resistant prostate cancer (mCRPC),
resistance to androgen receptor (AR)-targeted therapies, such as enzalutamide, remains an …

Abstract Purpose: PI3K–Akt–mTOR and androgen receptor (AR) signaling are commonly
aberrantly activated in metastatic castration-resistant prostate cancer (mCRPC), with PTEN …

Abstract The PI3K/AKT/PTEN pathway is frequently deregulated in metastatic castration-
resistant prostate cancer (mCRPC). ProCAID was a phase 2 trial assessing addition of the …

Summary Background The PI3K/AKT and androgen-receptor pathways are dysregulated in
metastatic castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN …

Abstract Background The phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt)
signalling axis and androgen receptor (AR) pathways exhibit reciprocal feedback regulation …

PURPOSE Capivasertib is a pan-AKT inhibitor. Preclinical data indicate activity in metastatic
castration-resistant prostate cancer (mCRPC) and synergism with docetaxel. PATIENTS …

Background PI3K/AKT and androgen receptor (AR) signalling are dysregulated in mCRPC.
PTEN loss (40%-50% of mCRPC) results in activation of AKT, the ipat target, and worse …

5008 Background: Androgen receptor (AR) signaling is an important growth mechanism in
mCRPC, providing the rationale for treatment with AR axis inhibitors such as ENZ and AAP …